Features
Avoiding Incisional Glaucoma Surgery
Selective laser trabeculoplasty and some MIGS could reduce the need for incisional surgery.
By Nathan Radcliffe, MD
An Update on Current Bleb Management
Optimize outcomes by refining trabeculectomy technique.
By Joseph F. Panarelli, MD, Rachel Lee, MD
Paradigm Shift in the Medical Management of Glaucoma
New medications and formulations are changing glaucoma treatment.
By Constance O. Okeke, MD, MSCE, Samantha Dewundara, MD
Pathology of the Outflow System
Better understanding is key to targeted glaucoma treatment.
By Mark J. Gallardo, MD
The Continuing Evolution of Xen
Thinking outside the eye.
By Davinder S. Grover, MD, MPH, Ronald L. Fellman, MD
WEB EXCLUSIVE: Sustained-Release Technologies for Glaucoma: The Unmet Need
Part 1 of a 4-part physician roundtable on developing advances.
WEB EXCLUSIVE: Sustained-Release Technologies for Glaucoma: Devices on the Near Horizon
Part 2 of a 4-part physician roundtable on developing advances.
WEB EXCLUSIVE: Sustained-Release Technologies for Glaucoma: Devices on the Far Horizon
Part 3 of a 4-part physician roundtable on developing advances.
WEB EXCLUSIVE: Sustained-Release Technologies for Glaucoma: Adoption
Part 4 of a 4-part physician roundtable on developing advances.
Web Exclusives
FDA Will Review Sustained-Release Bimatoprost Implant
By Jerry Helzner, contributing editor
Ocular Therapeutix 90-Day Insert Barely Misses Endpoint
By Jerry Helzner, contributing editor
Hydrus Registry Results Presented
By Jerry Helzner, contributing editor
iStent Effective at 3 Years in “Real-World” Study
By Jerry Helzner, contributing editor
Aerpio Studying AKB-9778 for Glaucoma
By Jerry Helzner, contributing editor
Zeiss Enters MIGS Space With Acquisition
By Jerry Helzner, contributing editor
Regenerating Retinal Ganglion Cells
By Jerry Helzner, contributing editor
iSTAR MIGS Procedure Effective at 18 Months
By Jerry Helzner, contributing editor
Microstent Trimmers Launched to Trim Stent Protrusions
By Jerry Helzner, contributing editor
Nicox Glaucoma Medication Begins Phase 2 Trial
By Jerry Helzner, contributing editor
Program Offers Easy Access to Xelpros
By Jerry Helzner, contributing editor
Medical Marijuana Sellers Still Recommend It for Glaucoma
By Jerry Helzner, contributing editor
Catalyst for a Cure Begins New Research Phase
By Jerry Helzner, contributing editor
Glaukos Licenses Novel Drug-Delivery Platform
By Jerry Helzner, contributing editor
PolyActiva Studies Sustained-Release Glaucoma Implant
By Jerry Helzner, contributing editor
Tears Could Provide Clues to Glaucoma Diagnosis
By Jerry Helzner, contributing editor
Glaukos Achieves Strong Sales Growth
By Jerry Helzner, contributing editor
Departments
From the Editor: The Change Constant in Glaucoma
The field is constantly evolving.
By Nathan Radcliffe, MD
Coding: Telemedicine and Remote Physiologic Monitoring
Recent coding changes could improve glaucoma care.
By Kevin J. Corcoran, COE, FNAO
Dogma vs Data: Audible Pops During Trans-scleral Cyclophotocoagulation
How many and how often?
By LEON W. HERNDON, MD, Ryan Machiele, BA
Product Spotlight: Test Provides New Insight Into Cell Health
Physicians can make more informed treatment decisions.
By Karen Appold, contributing writer